ofirnoflast + semaglutide

Ofirnoflast + semaglutide is an investigational **combination therapy** being evaluated in clinical trials for the treatment of **obesity** in patients with type 2 diabetes mellitus (T2DM). The combination consists of **ofirnoflast**, a first-in-class, orally bioavailable **NEK7 inhibitor** targeting the **NLRP3 inflammasome pathway** to suppress innate immunity-driven inflammation, and **semaglutide**, a subcutaneously administered **glucagon-like peptide 1 (GLP-1) receptor agonist** indicated for glycemic control and weight loss. The rationale for the combination is to augment weight loss and metabolic benefits by coupling the anti-inflammatory actions of ofirnoflast with the metabolic and appetite-suppressing effects of semaglutide. Preclinical and early-phase clinical data suggest that the combination may lead to greater weight loss and improved lean mass retention compared to semaglutide alone[1][2][3][4][6].

Brand names

OzempicWegovyRybelsus

Other names

HT-6184 + semaglutideOfirnoflast and Semaglutide